{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:27:11Z","timestamp":1789194431686,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Metastatic castration-resistant prostate cancer (mCRPC) frequently leads to bone and soft tissue metastases, leading to poor prognosis. The beta-emitting radioligand [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 targets the prostate-specific membrane antigen (PSMA) and may be less efficient against micrometastatic disease. The alpha-emitting radioligand [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-AB001 could offer enhanced treatment by delivering high energy over a short range. This study compared the efficacy of [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-AB001 and [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Binding and internalisation of radioligands were evaluated in PC-3 PIP-luc cells. A mouse model was established by intracardiac injection of these cells. Treatments with 0.24\u20121.0 MBq [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-AB001 or 22\u201266 MBq [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 were initiated 7 d post-cell inoculation. Metastatic burden was measured using bioluminescence imaging, and PSMA-targeted uptake was determined with [\n                      <jats:sup>18<\/jats:sup>\n                      F]F-PSMA-1007 \u00b5PET\/\u00b5CT. Gamma-autoradiography evaluated [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-AB001 distribution, and bone metastases were identified by radiography.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both radioligands displayed comparable in vitro binding. In vivo studies revealed metastatic formation in clinically relevant organs. \u00b5PET\/\u00b5CT demonstrated increased [\n                      <jats:sup>18<\/jats:sup>\n                      F]F-PSMA-1007 uptake in metastases, matching the bioluminescence imaging results. Focal [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-AB001 distribution in the metastatic xenograft indicated heterogeneously distributed micrometastases in the organs. A median survival up to 47 d was achieved with [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-AB001, compared to 25 d for controls and 27 d for [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617. An activity-dependent reduction in bone metastases was observed for [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617, while no bone lesions were detected in [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-AB001-treated mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>212<\/jats:sup>\n                      Pb]Pb-AB001 showed significant efficacy against micrometastases and advantages over [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 in preventing or treating early bone metastases for the investigated injected activities. This implies clinical potential for treating mCRPC, including patients at risk of early metastatic disease, but further studies including dosimetry and toxicity analyses are required with regards to activity levels.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07330-y","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:42:54Z","timestamp":1747802574000},"page":"4847-4859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer"],"prefix":"10.1007","volume":"52","author":[{"given":"Anna Julie Kj\u00f8l","family":"H\u00f8yvik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Kvassheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Wiig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiril","family":"Hillestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona-Elisabeth","family":"Revheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rugile","family":"Liukaityte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind","family":"Bruland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9426-0062","authenticated-orcid":false,"given":"Asta","family":"Juzeniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"7330_CR1","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180\u201392. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02799.x.","journal-title":"Int J Clin Pract"},{"key":"7330_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.21873\/cdp.10376","volume":"4","author":"T Nishino","year":"2024","unstructured":"Nishino T, Yamamoto S, Numao N, Komai Y, Oguchi T, Yasuda Y, et al. Predictors of progression to Castration-resistant prostate Cancer after radical prostatectomy in High-risk prostate Cancer patients. Cancer Diagn Progn. 2024;4:646\u201351. https:\/\/doi.org\/10.21873\/cdp.10376.","journal-title":"Cancer Diagn Progn"},{"key":"7330_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2016.06.011","volume":"96","author":"DM Moreira","year":"2016","unstructured":"Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, et al. Predictors of time to metastasis in Castration-resistant prostate Cancer. Urology. 2016;96:171\u20136. https:\/\/doi.org\/10.1016\/j.urology.2016.06.011.","journal-title":"Urology"},{"key":"7330_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41391-022-00573-y","volume":"26","author":"AP Mitchell","year":"2023","unstructured":"Mitchell AP, Meza AM, Panageas KS, Lipitz-Snyderman A, Farooki A, Morris MJ. Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2023;26:126\u201332. https:\/\/doi.org\/10.1038\/s41391-022-00573-y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"7330_CR5","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/pros.24549","volume":"83","author":"T Derlin","year":"2023","unstructured":"Derlin T, Riethdorf S, Schumacher U, Lafos M, Peine S, Coith C, et al. PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy. Prostate. 2023;83:1076\u201388. https:\/\/doi.org\/10.1002\/pros.24549.","journal-title":"Prostate"},{"key":"7330_CR6","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.1158\/1078-0432.Ccr-07-1506","volume":"13","author":"DC Danila","year":"2007","unstructured":"Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:7053\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-1506.","journal-title":"Clin Cancer Res"},{"key":"7330_CR7","doi-asserted-by":"publisher","unstructured":"Nakamura S, Nagata M, Nagaya N, Ashizawa T, Hirano H, Lu Y, et al. The detection and negative reversion of Circulating tumor cells as prognostic biomarkers for metastatic Castration-Resistant prostate Cancer with bone metastases treated by enzalutamide. Cancers (Basel). 2024;16. https:\/\/doi.org\/10.3390\/cancers16040772.","DOI":"10.3390\/cancers16040772"},{"key":"7330_CR8","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic Castration-Resistant prostate Cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"7330_CR9","unstructured":"ICRP. Nuclear Decay Data for Dosimetric Calculations. ICRP Publication 107. 2008."},{"key":"7330_CR10","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","volume":"63","author":"C Schuchardt","year":"2022","unstructured":"Schuchardt C, Zhang J, Kulkarni HR, Chen X, M\u00fcller D, Baum RP. Prostate-Specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic Castration-Resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. J Nucl Med. 2022;63:1199\u2013207. https:\/\/doi.org\/10.2967\/jnumed.121.262713.","journal-title":"J Nucl Med"},{"key":"7330_CR11","doi-asserted-by":"crossref","unstructured":"Miyazawa Y, Konik A, Otani K, Pittie R, Rodden D, Kelly J et al. Circulating tumor cell molecular signatures of response to 177Lu-PSMA-617 therapy in metastatic prostate cancer patients. J Nucl Med; 2024. p. 241193.","DOI":"10.1016\/j.ijrobp.2024.07.120"},{"key":"7330_CR12","doi-asserted-by":"publisher","unstructured":"Jalloul W, Ghizdovat V, Stolniceanu CR, Ionescu T, Grierosu IC, Pavaleanu I, et al. Targeted Alpha Therapy: All We Need to Know about (225)Ac\u2019s Physical Characteristics and Production as a Potential Theranostic Radionuclide. Pharmaceuticals (Basel). 2023;16. https:\/\/doi.org\/10.3390\/ph16121679.","DOI":"10.3390\/ph16121679"},{"key":"7330_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","volume":"79","author":"B Feuerecker","year":"2021","unstructured":"Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, et al. Activity and adverse events of Actinium-225-PSMA-617 in advanced metastatic Castration-resistant prostate Cancer after failure of Lutetium-177-PSMA. Eur Urol. 2021;79:343\u201350. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.013.","journal-title":"Eur Urol"},{"key":"7330_CR14","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.2967\/jnumed.123.265433","volume":"64","author":"C Meyer","year":"2023","unstructured":"Meyer C, Stuparu A, Lueckerath K, Calais J, Czernin J, Slavik R, Dahlbom M. Tandem isotope therapy with (225)Ac- and (177)Lu-PSMA-617 in a murine model of prostate Cancer. J Nucl Med. 2023;64:1772\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.265433.","journal-title":"J Nucl Med"},{"key":"7330_CR15","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.7150\/thno.42228","volume":"10","author":"AD Stuparu","year":"2020","unstructured":"Stuparu AD, Meyer CAL, Evans-Axelsson SL, L\u00fcckerath K, Wei LH, Kim W, et al. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study. Theranostics. 2020;10:2612\u201320. https:\/\/doi.org\/10.7150\/thno.42228.","journal-title":"Theranostics"},{"key":"7330_CR16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2967\/jnumed.123.266774","volume":"65","author":"R Zimmermann","year":"2024","unstructured":"Zimmermann R. Is (212)Pb really happening?? The Post-(177)Lu\/(225)Ac blockbuster?? J Nucl Med. 2024;65:176\u20137. https:\/\/doi.org\/10.2967\/jnumed.123.266774.","journal-title":"J Nucl Med"},{"key":"7330_CR17","doi-asserted-by":"publisher","unstructured":"Kokov KV, Egorova BV, German MN, Klabukov ID, Krasheninnikov ME, Larkin-Kondrov AA, et al. (212)Pb: production approaches and targeted therapy applications. Pharmaceutics. 2022;14. https:\/\/doi.org\/10.3390\/pharmaceutics14010189.","DOI":"10.3390\/pharmaceutics14010189"},{"key":"7330_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40658-022-00481-z","volume":"9","author":"M Kvassheim","year":"2022","unstructured":"Kvassheim M, Revheim MR, Stokke C. Quantitative SPECT\/CT imaging of lead-212: a Phantom study. EJNMMI Phys. 2022;9:52. https:\/\/doi.org\/10.1186\/s40658-022-00481-z.","journal-title":"EJNMMI Phys"},{"key":"7330_CR19","doi-asserted-by":"crossref","unstructured":"Berner K, Hernes E, Kvassheim M, Revheim M-E, Bastiansen J, Selboe S et al. First-in-human study of AB001, a prostate-specific membrane antigen (PSMA) targeted 212Pb alpha radioligand, in patients with metastatic castration resistant prostate cancer (mCRPC): Phase 0 experience. EMUC24\u201316th European Multidisciplinary Congress on Urological Cancers. Lisbon, Portugal; 2024.","DOI":"10.1016\/S2666-1683(24)01229-1"},{"key":"7330_CR20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269299","author":"K Berner","year":"2025","unstructured":"Berner K, Hernes E, Kvassheim M, Revheim ME, Bastiansen J, Selboe S, et al. First-in-Human phase 0 study of AB001, a prostate-Specific membrane Antigen-Targeted (212)Pb Radioligand, in patients with metastatic Castration-Resistant prostate Cancer. J Nucl Med. 2025. https:\/\/doi.org\/10.2967\/jnumed.124.269299.","journal-title":"J Nucl Med"},{"key":"7330_CR21","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2967\/jnumed.123.267189","volume":"65","author":"MR Griffiths","year":"2024","unstructured":"Griffiths MR, Pattison DA, Latter M, Kuan K, Taylor S, Tieu W, et al. First-in-Human 212Pb-PSMA\u2013Targeted \u03b1-Therapy SPECT\/CT imaging in a patient with metastatic Castration-Resistant prostate Cancer. J Nucl Med. 2024;65:664. https:\/\/doi.org\/10.2967\/jnumed.123.267189.","journal-title":"J Nucl Med"},{"key":"7330_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40658-023-00571-6","volume":"10","author":"M Kvassheim","year":"2023","unstructured":"Kvassheim M, Tornes AJK, Juzeniene A, Stokke C, Revheim MR. Imaging of (212)Pb in mice with a clinical SPECT\/CT. EJNMMI Phys. 2023;10:47. https:\/\/doi.org\/10.1186\/s40658-023-00571-6.","journal-title":"EJNMMI Phys"},{"key":"7330_CR23","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","volume":"63","author":"ES Delpassand","year":"2022","unstructured":"Delpassand ES, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A, N\u00fa\u00f1ez R. Targeted \u03b1-Emitter therapy with (212)Pb-DOTAMTATE for the treatment of metastatic SSTR-Expressing neuroendocrine tumors: First-in-Humans Dose-Escalation clinical trial. J Nucl Med. 2022;63:1326\u201333. https:\/\/doi.org\/10.2967\/jnumed.121.263230.","journal-title":"J Nucl Med"},{"key":"7330_CR24","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/coc.0000000000000353","volume":"41","author":"RF Meredith","year":"2018","unstructured":"Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, et al. Safety and outcome measures of First-in-Human intraperitoneal \u03b1 radioimmunotherapy with 212Pb-TCMC-Trastuzumab. Am J Clin Oncol. 2018;41:716\u201321. https:\/\/doi.org\/10.1097\/coc.0000000000000353.","journal-title":"Am J Clin Oncol"},{"key":"7330_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2967\/jnumed.119.229393","volume":"61","author":"SR Banerjee","year":"2020","unstructured":"Banerjee SR, Minn I, Kumar V, Josefsson A, Lisok A, Brummet M, et al. Preclinical evaluation of (203\/212)Pb-Labeled Low-Molecular-Weight compounds for targeted radiopharmaceutical therapy of prostate Cancer. J Nucl Med. 2020;61:80\u20138. https:\/\/doi.org\/10.2967\/jnumed.119.229393.","journal-title":"J Nucl Med"},{"key":"7330_CR26","doi-asserted-by":"publisher","unstructured":"Stenberg VY, Larsen RH, Ma LW, Peng Q, Juzenas P, Bruland \u00d8S, Juzeniene A. Evaluation of the PSMA-Binding ligand (212)Pb-NG001 in multicellular tumour spheroid and mouse models of prostate Cancer. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22094815.","DOI":"10.3390\/ijms22094815"},{"key":"7330_CR27","doi-asserted-by":"publisher","unstructured":"Stenberg VY, Tornes AJK, Nilsen HR, Revheim ME, Bruland \u00d8S, Larsen RH, Juzeniene A. Factors influencing the therapeutic efficacy of the PSMA targeting radioligand (212)Pb-NG001. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14112784.","DOI":"10.3390\/cancers14112784"},{"key":"7330_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13046-023-02636-x","volume":"42","author":"J Li","year":"2023","unstructured":"Li J, Huang T, Hua J, Wang Q, Su Y, Chen P, et al. CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment. J Experimental Clin Cancer Res. 2023;42:61. https:\/\/doi.org\/10.1186\/s13046-023-02636-x.","journal-title":"J Experimental Clin Cancer Res"},{"key":"7330_CR29","doi-asserted-by":"crossref","unstructured":"Strosberg JR, Naqvi S, Cohn AL, Delpassand E, Wagner VJ, Torgue J, et al. Safety, tolerability and efficacy of Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR plus GEP-NETs): A phase 2 study. Journal of Clinical Oncology; 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.4020"},{"key":"7330_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jlcr.3825","volume":"63","author":"VY Stenberg","year":"2020","unstructured":"Stenberg VY, Juzeniene A, Chen Q, Yang X, Bruland \u00d8S, Larsen RH. Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [(212) Pb]Pb-NG001 for prostate cancer. J Label Comp Radiopharm. 2020;63:129\u201343. https:\/\/doi.org\/10.1002\/jlcr.3825.","journal-title":"J Label Comp Radiopharm"},{"key":"7330_CR31","unstructured":"Larsen RH. Production of highly purified 212Pb. 2010."},{"key":"7330_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2967\/jnumed.122.264009","volume":"64","author":"RG Li","year":"2023","unstructured":"Li RG, Stenberg VY, Larsen RH. An experimental generator for production of High-Purity (212)Pb for use in radiopharmaceuticals. J Nucl Med. 2023;64:173\u20136. https:\/\/doi.org\/10.2967\/jnumed.122.264009.","journal-title":"J Nucl Med"},{"key":"7330_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2174\/1874471013666200511000532","volume":"13","author":"VY Stenberg","year":"2020","unstructured":"Stenberg VY, Juzeniene A, Bruland \u00d8S, Larsen RH. In situ generated (212)Pb-PSMA ligand in a (224)Ra-Solution for dual targeting of prostate Cancer sclerotic stroma and PSMA-positive cells. Curr Radiopharm. 2020;13:130\u201341. https:\/\/doi.org\/10.2174\/1874471013666200511000532.","journal-title":"Curr Radiopharm"},{"key":"7330_CR34","doi-asserted-by":"publisher","first-page":"A429","DOI":"10.1136\/jitc-2020-SITC2020.0717","volume":"8","author":"K L\u00fcckerath","year":"2020","unstructured":"L\u00fcckerath K, Bailis J, Current K, Salvati M, Radu C, Czernin J. 717\u2005AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE\u00ae immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy. J Immunother Cancer. 2020;8:A429\u201330. https:\/\/doi.org\/10.1136\/jitc-2020-SITC2020.0717.","journal-title":"J Immunother Cancer"},{"key":"7330_CR35","doi-asserted-by":"publisher","unstructured":"Labitzky V, Baranowsky A, Maar H, Hanika S, Starzonek S, Ahlers AK, et al. Modeling spontaneous bone metastasis formation of solid human tumor xenografts in mice. Cancers (Basel). 2020;12. https:\/\/doi.org\/10.3390\/cancers12020385.","DOI":"10.3390\/cancers12020385"},{"key":"7330_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27\u201331. https:\/\/doi.org\/10.4103\/0976-0105.177703.","journal-title":"J Basic Clin Pharm"},{"key":"7330_CR37","unstructured":"Prasad V, Trikalinos N, Hanna A, Johnson F, Puhlmann M, Wahl R. A phase I\/IIa of [212Pb]VMT-NET targeted Alpha-Particle therapy for advanced SSTR2 positive neuroendocrine tumors. J Nucl Med. 2024;65."},{"key":"7330_CR38","doi-asserted-by":"crossref","unstructured":"Hansen AR, Pattison DA, Ngai S, Karmann A, Walker AJ, Campbell L, et al. Phase Ib\/IIa dose escalation and expansion study of [<\u2009sup\u2009>\u2009212\u2009Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb\u2013phase I\/II study. Journal of Clinical Oncology. 2025;43:TPS275-TPS. doi:10.1200\/JCO.2025.43.5_suppl.TPS275.","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS275"},{"key":"7330_CR39","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1007\/s00259-022-05837-2","volume":"49","author":"VJ Tschan","year":"2022","unstructured":"Tschan VJ, Borgna F, Busslinger SD, Stirn M, Rodriguez JMM, Bernhardt P, et al. Preclinical investigations using [(177)Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49:3639\u201350. https:\/\/doi.org\/10.1007\/s00259-022-05837-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7330_CR40","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","volume":"46","author":"C M\u00fcller","year":"2019","unstructured":"M\u00fcller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1919\u201330. https:\/\/doi.org\/10.1007\/s00259-019-04345-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7330_CR41","doi-asserted-by":"publisher","first-page":"17800","DOI":"10.1038\/s41598-019-54150-w","volume":"9","author":"CA Umbricht","year":"2019","unstructured":"Umbricht CA, K\u00f6ster U, Bernhardt P, Gracheva N, Johnston K, Schibli R, et al. Alpha-PET for prostate cancer: preclinical investigation using (149)Tb-PSMA-617. Sci Rep. 2019;9:17800. https:\/\/doi.org\/10.1038\/s41598-019-54150-w.","journal-title":"Sci Rep"},{"key":"7330_CR42","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2967\/jnumed.115.170423","volume":"57","author":"E Hindi\u00e9","year":"2016","unstructured":"Hindi\u00e9 E, Zanotti-Fregonara P, Quinto MA, Morgat C, Champion C. Dose deposits from 90Y, 177Lu, 111In, and 161\u00a0tb in micrometastases of various sizes: implications for radiopharmaceutical therapy. J Nucl Med. 2016;57:759\u201364. https:\/\/doi.org\/10.2967\/jnumed.115.170423.","journal-title":"J Nucl Med"},{"key":"7330_CR43","first-page":"521","volume":"35","author":"SM Goddu","year":"1994","unstructured":"Goddu SM, Rao DV, Howell RW. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med. 1994;35:521\u201330.","journal-title":"J Nucl Med"},{"key":"7330_CR44","doi-asserted-by":"publisher","unstructured":"Feinendegen LE, McClure JJ. Alpha-Emitters for medical therapy: workshop of the united States department of energy: Denver, Colorado, May 30\u201331, 1996. Radiat Res. 1997;148. https:\/\/doi.org\/10.2307\/3579579.","DOI":"10.2307\/3579579"},{"key":"7330_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2967\/jnumed.108.058651","volume":"51","author":"G Sgouros","year":"2010","unstructured":"Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD pamphlet 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311\u201328. https:\/\/doi.org\/10.2967\/jnumed.108.058651.","journal-title":"J Nucl Med"},{"key":"7330_CR46","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2967\/jnumed.120.256263","volume":"62","author":"AD Stuparu","year":"2021","unstructured":"Stuparu AD, Capri JR, Meyer CAL, Le TM, Evans-Axelsson SL, Current K, et al. Mechanisms of resistance to prostate-Specific membrane Antigen\u2013Targeted radioligand therapy in a mouse model of prostate Cancer. J Nucl Med. 2021;62:989\u201395. https:\/\/doi.org\/10.2967\/jnumed.120.256263.","journal-title":"J Nucl Med"},{"key":"7330_CR47","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1002\/cncr.29455","volume":"121","author":"JF Chen","year":"2015","unstructured":"Chen JF, Ho H, Lichterman J, Lu YT, Zhang Y, Garcia MA, et al. Subclassification of prostate cancer Circulating tumor cells by nuclear size reveals very small nuclear Circulating tumor cells in patients with visceral metastases. Cancer. 2015;121:3240\u201351. https:\/\/doi.org\/10.1002\/cncr.29455.","journal-title":"Cancer"},{"key":"7330_CR48","doi-asserted-by":"publisher","first-page":"8032","DOI":"10.1038\/s41598-019-44401-1","volume":"9","author":"S Ribeiro-Samy","year":"2019","unstructured":"Ribeiro-Samy S, Oliveira MI, Pereira-Veiga T, Muinelo-Romay L, Carvalho S, Gaspar J, et al. Fast and efficient microfluidic cell filter for isolation of Circulating tumor cells from unprocessed whole blood of colorectal cancer patients. Sci Rep. 2019;9:8032. https:\/\/doi.org\/10.1038\/s41598-019-44401-1.","journal-title":"Sci Rep"},{"key":"7330_CR49","doi-asserted-by":"publisher","first-page":"e61770","DOI":"10.1371\/journal.pone.0061770","volume":"8","author":"FA Coumans","year":"2013","unstructured":"Coumans FA, van Dalum G, Beck M, Terstappen LW. Filter characteristics influencing Circulating tumor cell enrichment from whole blood. PLoS ONE. 2013;8:e61770. https:\/\/doi.org\/10.1371\/journal.pone.0061770.","journal-title":"PLoS ONE"},{"key":"7330_CR50","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1021\/acs.molpharmaceut.7b00877","volume":"15","author":"M Bene\u0161ov\u00e1","year":"2018","unstructured":"Bene\u0161ov\u00e1 M, Umbricht CA, Schibli R, M\u00fcller C, Albumin-Binding PSMA, Ligands. Optimization of the tissue distribution profile. Mol Pharm. 2018;15:934\u201346. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00877.","journal-title":"Mol Pharm"},{"key":"7330_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05446-5","author":"VJ Tschan","year":"2021","unstructured":"Tschan VJ, Borgna F, Schibli R, M\u00fcller C. Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05446-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7330_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13550-017-0257-4","volume":"7","author":"CA Umbricht","year":"2017","unstructured":"Umbricht CA, Bene\u0161ov\u00e1 M, Schmid RM, T\u00fcrler A, Schibli R, van der Meulen NP, M\u00fcller C. (44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617-preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617. EJNMMI Res. 2017;7:9. https:\/\/doi.org\/10.1186\/s13550-017-0257-4.","journal-title":"EJNMMI Res"},{"key":"7330_CR53","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.2967\/jnumed.116.174300","volume":"57","author":"AP Kiess","year":"2016","unstructured":"Kiess AP, Minn I, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, et al. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic acid for PSMA-Targeted \u03b1-Particle radiopharmaceutical therapy. J Nucl Med. 2016;57:1569\u201375. https:\/\/doi.org\/10.2967\/jnumed.116.174300.","journal-title":"J Nucl Med"},{"key":"7330_CR54","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2967\/jnumed.121.262098","volume":"63","author":"RC Mease","year":"2022","unstructured":"Mease RC, Kang CM, Kumar V, Banerjee SR, Minn I, Brummet M, et al. An improved (211)At-Labeled agent for PSMA-Targeted \u03b1-Therapy. J Nucl Med. 2022;63:259\u201367. https:\/\/doi.org\/10.2967\/jnumed.121.262098.","journal-title":"J Nucl Med"},{"key":"7330_CR55","doi-asserted-by":"publisher","first-page":"980","DOI":"10.2967\/jnumed.120.256388","volume":"62","author":"SR Banerjee","year":"2021","unstructured":"Banerjee SR, Lisok A, Minn I, Josefsson A, Kumar V, Brummet M, et al. Preclinical evaluation of (213)Bi- and (225)Ac-Labeled Low-Molecular-Weight compounds for radiopharmaceutical therapy of prostate Cancer. J Nucl Med. 2021;62:980\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.256388.","journal-title":"J Nucl Med"},{"key":"7330_CR56","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1053\/j.semnuclmed.2022.02.002","volume":"52","author":"SS Adler","year":"2022","unstructured":"Adler SS, Seidel J, Choyke PL. Advances in preclinical PET. Semin Nucl Med. 2022;52:382\u2013402. https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.02.002.","journal-title":"Semin Nucl Med"},{"key":"7330_CR57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cpet.2020.06.003","volume":"15","author":"M Amirrashedi","year":"2020","unstructured":"Amirrashedi M, Zaidi H, Ay MR. Advances in preclinical PET instrumentation. PET Clin. 2020;15:403\u201326. https:\/\/doi.org\/10.1016\/j.cpet.2020.06.003.","journal-title":"PET Clin"},{"key":"7330_CR58","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2967\/jnumed.122.264455","volume":"64","author":"LTG Mikalsen","year":"2023","unstructured":"Mikalsen LTG, Kvassheim M, Stokke C. Optimized SPECT imaging of (224)Ra \u03b1-Particle therapy by (212)Pb photon emissions. J Nucl Med. 2023;64:1131\u20137. https:\/\/doi.org\/10.2967\/jnumed.122.264455.","journal-title":"J Nucl Med"},{"key":"7330_CR59","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/cncr.24896","volume":"116","author":"T Ibrahim","year":"2010","unstructured":"Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer. 2010;116:1406\u201318. https:\/\/doi.org\/10.1002\/cncr.24896.","journal-title":"Cancer"},{"key":"7330_CR60","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/sj.cr.7290266","volume":"15","author":"JJ Yin","year":"2005","unstructured":"Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res. 2005;15:57\u201362. https:\/\/doi.org\/10.1038\/sj.cr.7290266.","journal-title":"Cell Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07330-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07330-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07330-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T07:31:54Z","timestamp":1762327914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07330-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":60,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7330"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07330-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were carried out in accordance with European Directive 2010\/63\/EU. The studies were approved by the Institutional Committee on Research Animal Care and the Norwegian Food Safety Authority (FOTS-ID 30148 and 30625; Brumunddal, Norway).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"\u00d8. Bruland holds ownership interests in ARTBIO AS.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}